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Antibody mediated rejection (AMR) poses a signiﬁcant and continued challenge for long term graft survival in kidney trans-
plantation. However, in the recent years, there has emerged an increased understanding of the varied manifestations of the
antibody mediated processes in kidney transplantation. In this article, we brieﬂy discuss the various histopathological and clinical
manifestations of AMRs,along withdescribing thetechniques and methods which have made it easier todeﬁne anddiagnose these
rejections. We also review the emerging issues of C4d negative AMR, its signiﬁcance in long term allograft survival and provide a
brief summary of the current management strategies for managing AMRs in kidney transplantation.
1.Introduction
Antibody-mediated rejection is an important cause of acute
and chronic allograft dysfunction and graft loss. Although
hyperacute (i.e., preformed antibody-mediated) rejection
has been recognized since the 1960s, the role of antibodies in
other forms of rejection was not clear until new diagnostic
methods became available. Our knowledge about the role of
antibodies in allograft rejection, particularly in some forms
of chronic allograft rejection, has been evolving rapidly over
the last decade.
2.TypesofAntibody-MediatedRejection(AMR)
Antibodiesdirectedagainstdonorantigencancausediﬀerent
types of rejection that can vary in acuity and severity.
Hyperacute AMR. It occurs due to preformed donor speciﬁc
antibodies (DSA) present in high titers and presents as graft
failure that can occur within minutes (but sometimes may
be delayed for a few days) after transplantation [1]. The
occurrence of this type of rejection is extremely rare because
of the universal adoption of pretransplantation cross-
matching. The histopathology is characterized by features of
severe endothelial and arterial injury manifested as arteritis
(often transmural), interstitial edema, and severe cortical
necrosis, with almost all cases requiring allograft nephrecto-
my. Most of the initial cases were reported in patients with
a history of previous transplantation or in multiparous
women, suggesting the role of sensitization and preformed
antibodies. Strong proof for this was provided by Patel
and Terasaki in 1969 when they showed that 24 of the
30 patients with a pretransplant positive crossmatch had
immediategraftfailurecomparedwithonly8graftfailuresin
195 patients without a positive crossmatch [1].
Acute AMR. It is characterized by graft dysfunction mani-
festing over days and is a result of DSAs, that may either
be preformed or develop denovo after transplantation [2].
Acute AMR occurs in about 5–7% of all kidney transplants
and is responsible for 20–48% of acute rejection episodes
among presensitized positive crossmatch patients [3, 4].
Allograftdysfunctionwithresultantcreatinineelevationmay
not be present in all cases of AMR. Histopathology in these
patients is again related to endothelial injury mediated by
antibodies but is less severe than that seen in hyperacute
rejections. Biopsy often shows endothelial cell swelling,2 Journal of Transplantation
neutrophilic inﬁltration of glomeruli and peritubular cap-
illaries, ﬁbrin thrombi, interstitial edema, and hemorrhage
[5]. However, in a minority of these rejections, acute tu-
bular necrosis may be the only feature observed [3]. The
identiﬁcation of these AMRs has become easier with the de-
velopment of C4d-staining in biopsies and improved meth-
ods of antibody detection. Prior to the routine use of C4d-
staining, diagnosis was often limited by lack of staining for
antibody components and was often restricted to steroid-
resistant cases with or without obvious histopathologic
ﬁndings as described above.
Chronic AMR. It is now well recognized that antibodies can
mediate chronic allograft injury which is characteristi-
cally seen as transplant glomerulopathy (TG) on kidney bio-
psies [6]. TG (also known as or chronic allograft glomeru-
lopathy) is characterized by glomerular mesangial expansion
and capillary basement membrane (BM)duplication, seen as
basement membrane double contouring or splitting. Simi-
larly, the peritubular capillary (PTC) basement membrane
also shows changes, but these are seen mostly on electron
microscopy sections as basement membrane multilayering.
Clinically, the manifestations range from patients being as-
ymptomatic in the early stages to having nephrotic range
proteinuria, hypertension, and allograft dysfunction in the
advanced stages. Progression can sometimes be fairly rapid,
especially with ongoing acute AMR, resulting in graft failure
withinmonths[7].TheprevalenceofTGinprotocolbiopsies
has varied between 5% at 1yr to 20% at 5 years [8].
3. Pathogenesis
Antibodies are most commonly directed against human leu-
kocyte antigen (HLA)/major-histocompatibility-complex
(MHC) Class I and II antigens [9]. HLA class I antigens are
expressed on all nucleated cells, whereas HLA class II anti-
gens are restricted to antigen-presenting cells (B lympho-
cytes, dendritic cells) and endothelial cells. However, the
antibodies can also be directed against other donor speciﬁc
antigens such as MHC-class I-related chain A (MICA)
antigens, MHC-class I-related chain B (MICB) antigens,
platelet-speciﬁc antigens, molecules of the renin-angiotensin
pathway, and polymorphisms involving chemokines and
their receptors [10–15]. MICA antigens are expressed on
endothelial cells, dendritic cells, ﬁbroblasts, epithelial cells,
and many tumors, but not on peripheral-blood lympho-
cytes. Risk factors for sensitization against HLA I and II anti-
gens are pregnancy, blood transfusions, and previous trans-
plantation. However, blood transfusions were found not to
be a risk factor for MICA sensitization [10].
4. Mechanisms of Antibody Mediated Injury
Themajormechanisminvolvedisactivationofclassicalcom-
plement pathway by the antigen-antibody complex, lead-
ing to formation of the membrane attack complex result-
ing in cellular injury. The target antigens in AMR are most
often situated on the endothelium resulting in the histolog-
ical ﬁndings of acute (glomerulitis, peritubular capillaritis)
and chronic (transplant glomerulopathy) vascular injury.
Endothelial damage also results in platelet activation and
microthrombi formation. The byproducts of complement
activation (e.g., C3a and C5a) act as chemokines resulting
in inﬂammatory cell inﬁltration and ampliﬁcation of the in-
ﬂammatory process. Long standing inﬂammation results in
cell proliferation, basement membrane duplication, and me-
sangial interposition which can be easily seen on light and
electron microscopy as glomerular BM splitting and PTC
BM multilayering, respectively. The ability of diﬀerent IgG
subclasses to ﬁx complemsent also varies. IgG1 and IgG3
have strong complement ﬁxing properties compared to the
IgG2andIgG4subclasses,whichﬁxcomplementweakly.The
signiﬁcance of this was studied in a series of 74 patients with
pretransplant anti-HLA antibodies. Only 4 patients in this
series had exclusively weak or no complement ﬁxing HLA
antibodies (IgG2 or IgG4) [16]. Of the remaining, 21 and 46
patients had isolated strong complement ﬁxing HLA (IgG1
orIgG3)antibodiesoramixofweakandstrongcomplement
ﬁxing HLA antibodies respectively, but had no diﬀerence in
AMRorgraftfailureat5years.Ofthe4patientswithisolated
IgG2/IgG4, none had any AMR. Antibodies can also mediate
injury via complement independent mechanisms such as
antibody-cell-dependent cytotoxicity (ADCC). This is medi-
ated through cells of the innate immunity (natural killer
cells, macrophages) which get activated by binding to the
Fc receptor portion of the antibody [17]. Antigen antibody
interaction on endothelial cells is also known to increase Von
Willibrand Factor (vWF) along with externalization of P-
selectin molecules resulting in increased platelet activation
and leukocyte traﬃcking, respectively [18, 19].
5.DiagnosisofAMR
Based on the increasing evidence for the role of antibodies in
allograft dysfunction and the strong correlation with C4d-
staining and DSA, the Banﬀ committee updated its renal
allograft biopsy classiﬁcation to involve a separate antibody-
mediated rejection diagnosis [20]. According to the classiﬁ-
cation, AMR was deﬁned as a triad involving the presence of
DSA, positive C4d-staining on the biopsy, and histopatho-
logical evidence of antibody-mediated injury (glomerulitis,
peritubular capillaritis, and arteritis).
Based on the histopathology, AMR can be classiﬁed into
three subtypes as below.
Class I: Presence of acute tubular necrosis (ATN)
only, with minimal inﬂammation.
ClassII:glomerulitis,peritubularcapillaritis,andmi-
crothrombosis.
Class III: Arteritis.
Chronic AMR according to the Banﬀ criteria involves
demonstration of C4d, DSA, and at least one feature of mor-
phologic evidence of chronic tissue injury, such as glomer-
ular double contours, peritubular capillary basement mem-
brane multilayering, interstitial ﬁbrosis/tubular atrophy,Journal of Transplantation 3
and/or intimal thickening of arteries [20]. However, it is not
uncommon to have situations where DSAs may be absent
even in the presence of histological AMR and positive C4d-
staining.
6.C4dStain
C4d is a complement split product that is formed during
breakdown of C4b into C4d and C4c. C4d has a thioester
moiety that enables strong covalent bonding with the en-
dothelial cells and basement membrane. It is constitutively
expressed in all normal kidneys in the mesangium and the
vascular pole owing to the constant complement turnover.
This can extend into glomerular capillaries in cases of
immune-mediated glomerulopathies, but peritubular C4d
deposition is noted mostly in the transplanted kidney, with
rare reports of C4d presence in PTC of native kidneys [21,
22].
There are two methods for C4d detection in biopsy spec-
imens [23]. It can be detected using either immunoﬂuo-
rescence (IF) on frozen tissue with a monovalent antibody
against C4d or using Immunohistochemistry (IHC) on
paraﬃn-embeddedtissuewithapolyvalentantibody.Diﬀuse
C4d implies >50% of PTC staining for C4d, while focal
and minimal staining implies 10–50% and <10% staining,
respectively. IHC is less sensitive than IF for C4d detection.
Hence, focal staining on IHC may be equivalent to diﬀuse
staining with IF.
The association of C4d with AMR was initially described
by Feucht et al. in 1991 when they showed a signiﬁcant
association of C4d with preformed anti HLA antibodies
in patients with acute rejection [24]. This was subse-
quently conﬁrmed in a study of 16 biopsies with DSA and
histopathological evidence of AMR (neutrophilic capillari-
tis). All 16 biopsies with AMR showed diﬀuse C4d-staining
with trace or no staining in the biopsies with acute cellular
rejection (n = 14) and 5 of the 6 biopsies with cyclosporine
toxicity [25].Crespoetal.evaluatedDSAandC4dinsteroid-
resistant rejections and found positive DSA in 37% of the
cases. Among these, 95% had positive PTC C4d-staining
[26].
The data for C4d-staining in chronic AMR is more var-
iable, with a few studies showing strong correlation while
others showing poor correlation. Mauiyyedi et al. reported
presence of C4d in 23 of 38 biopsies with features of chronic
AMR (GBM duplication and arterial intimal ﬁbrosis) but no
C4d in the control group without features of chronic AMR
[27]. Similar strong associations of C4d with TG and per-
itubular basement membrane multilayering have been de-
scribed in other studies as well [28, 29]. However, some
studiesfoundnocorrelationbetweenpresenceofTGanddif-
fuse C4d, with many TG patients showing no C4d positivity
[30, 31].
Protocol biopsy studies have also demonstrated another
important characteristic of C4d which is variability of stain-
ing over time, suggesting a constant ﬂux between states of
positivetonegativeC4d[32].Inasigniﬁcantnumberofthese
biopsies, there was presence of microvascular inﬂammation
(PTC and glomerular capillaritis) in spite of negative C4d-
staining [32]. Another recent development has been the
identiﬁcation that certain endothelial transcripts appear to
be expressed more often in patients with histological features
ofAMRevenintheabsenceofC4d-staining. Sisetal.studied
a number of endothelial-associated transcripts (ENDAT) in
kidney transplants and found that the ENDAT expression
w a sh i g h e ri na l lt yp e so fr e j e c t i o nb u tm o r es oi nA M R .F u r -
thermore, about 40% of patients with ENDAT and chronic
AMRfeaturesdemonstratednoC4d-staining.Therewasalso
a strong correlation between elevated ENDAT and presence
of anti-HLA antibodies, particularly HLA Class II antibodies
[33]. The biology of this ENDAT expression appears to be
related to the process of endothelial cell activation, repair,
andangiogenesis whicharewellknown mechanisms of AMR
[33]. This, along with the low sensitivity of C4d for chronic
AMR, has given rise to the concept of “C4d-negative AMR”
which appears to be as common, if not more than the C4d-
positive AMR and has similar poor prognosis in terms of
graft survival [33].
7.AntiHLAAntibodyDetection
The techniques to identify anti HLA antibodies have im-
proved signiﬁcantly with the development of single-bead an-
tigen testing methods which have very high sensitivity for
antibodydetection.Thecomplement-dependentcytotoxicity
(CDC) still remains the gold standard test for the detec-
tion of preformed antibodies prior to transplantation. The
addition of antihuman globulin enhances the sensitivity of
the assay by cross-linking the antibodies (AHG-CDC). Flow
cytometry crossmatch (FXM) assay is more sensitive than
the CDC assay and detects antibodies via ﬂuorochrome-
tagged antihuman Immunoglobulin antibody. The newer
solid phase assays use puriﬁed single HLA antigens to detect
anti-HLAantibodiesbyELISAorﬂowcytometrytechniques.
These tests have increased sensitivity to detect presence of
anti-HLA antibodies even with a negative FXM [34–36].
The strength of antibody detected in Luminex assays is indi-
cated by Mean Fluorescent Intensity (MFI). However, there
is poor standardization of these tests and the MFIs have been
found to vary between diﬀerent centers performing the same
test [37]. A further improvement in antibody detection
technique was reported by Yabu et al. They tested antibodies
for their capacity to ﬁx C1q complement and compared
them to regular IgG antibody detection and found a higher
speciﬁcityfortheC1qtechniqueindetectingantibodiesasso-
ciated with TG and poor graft outcomes [38]. This technique
may improve our ability to prognosticate the signiﬁcance of
DSAs but will need to be further standardized and validated
in a larger patient population.
8. Treatment
Although the current diagnosis of AMR requires the con-
comitant presence of DSA, C4d, and histopathological evi-
dence of AMR, treatment may be initiated in circumstances
where the above criteria may not be fulﬁlled in entirety. This4 Journal of Transplantation
depends on the risk factor proﬁle of the patient (sensitized
patient, history of pregnancies, and blood transfusions) and
presence or absence of organ dysfunction. Treatment is often
initiated in situations of diﬀuse C4d positivity with allograft
dysfunction even in the absence of DSA or histological evi-
dence of AMR. The inability to measure DSAs in these cases
may be related to the presence of non anti-HLA antibodies,
to antigen not present on the single-bead assays, or to the
possibility that the DSAs may be completely adsorbed onto
the allograft [39]. Similarly, patients with positive DSA and
histological evidence of AMR may not demonstrate any C4d
activity, and treatment is often initiated in these patients as
well, especially in the presence of allograft dysfunction. C4d
in such cases of acute AMR may be negative for a number
of reasons. Immunohistochemistry (IHC) is known to be
less sensitive compared to immunoﬂuorescence (IF) staining
[22, 23]. Also, areas with necrosis may stain falsely negative
for C4d and hence, care must be taken to ensure that viable
areas of the biopsy specimen are stained for C4d [22].
There is a paucity of randomized controlled trials in the
treatment of AMR. Many of the studies have used historical
controls to compare the eﬀectiveness of therapies. There is
also bound to be some publication bias related to selective
publication of positive studies.
Even with these inadequacies, there has been good
progress made in developing treatments for AMR. The pri-
mary goal in AMR treatment involves targeting the reduc-
tion/removal of DSAs and elimination of the B-cell/plasma
cell population responsible for the production of these anti-
bodies.
A number of treatment modalities have been employed
for the treatment of AMR as characterized below.
(1) Antibody removal/neutralization: plasmapheresis,
immunoadsorption, intravenous immunoglobulin,
and splenectomy.
(2) Anti B-Cell therapies: Mycophenolate mofetil, Ritux-
imab, IVIG, and splenectomy.
(3) Antiplasma cell therapy: Bortezomib.
(4) Anti-T-cell therapies: T-cell depleting agents such as
Antithymocyte globulin (ATG).
(5) Conversion to tacrolimus-based regimens.
(6) Terminal-complement pathway inhibitor: Eculizum-
ab.
The presence of a vast array of therapeutic modalities signi-
ﬁes the ineﬀectiveness of one drug or one particular combi-
nation therapy to reverse or treat AMR successfully in all sce-
narios. All of these treatments have been used in diﬀerent
combinations by diﬀerent groups without a good control
arm,resultinginpoorevidencetoargueforthesuperiorityof
one treatment regimen. These treatment modalities are also
used for pretransplantation desensitization protocols to ab-
rogate positive crossmatch in highly sensitized patients.
8.1. Intravenous Immunoglobulin (IVIG). This is the most
commonly used agent either alone or often, in combina-
tion with plasmapheresis. Although the exact mechanisms
involved are not clear, they appear to involve multiple pro-
cesses such as neutralization of complement ﬁxing antibod-
ies, alteration in the activity of complement, modulation of
Fc receptor activation and function, and regulation of T and
Bl y m p h o c y t e s[ 40]. Recent research has elucidated the pos-
sible role in this immunomodulation, for a speciﬁc subtype
of IgG which possesses sialylated glycan residues near the Fc
receptor [41] .T h e s es i a l y l a t e dI g G sw e r es h o w nt ob i n dt o
lectin receptor SIGN-R1 or DC-SIGN leading to increased
expression of inhibitory Fc receptor (FcR), FcgammaRIIb
on inﬂammatory cells, thereby attenuating inﬂammation
[41, 42]. IVIG is routinely used in one of two doses: high
(2gm/kg) or low (100mg/kg per session). Low-dose IVIG
is mostly used in combination with plasmapheresis where it
may help replenish depleted IGs. Initial studies used IVIG
at high-doses without plasmapheresis and described a fair
degree of success in desensitization prior to transplant and
also for treating antibody-mediated rejection [43, 44]. IVIG
is generally safe and well tolerated in most patients with
occasional side eﬀects such as aseptic meningitis, volume
overload, and rarely acute kidney injury possibly related to
high osmotic load. Sucrose-based IVIG preparation is to be
avoided, while glycine-based preparations are relatively safe.
8.2. Plasmapheresis (PP). Plasmapheresis is very eﬀective
in reducing the antibody load but needs to be used in
conjunction with other therapies that target the anti-
body producing mechanisms. The most common type of
Plasmapheresis performed is plasma exchange, with albumin
being the most common replacement ﬂuid used. It is
usually performed on alternate days with a 1–1.5 volume
exchange with albumin (commonly) or fresh frozen plasma.
Most institutions also follow each PP session with low-
dose IVIG (100mg/kg) [45]. DSAs are monitored along
with renal function to document the eﬀectiveness of the
therapy. Treatment, if successful, is continued until the
level of antibodies has dropped to safe levels along with
improvement in renal function. One of the early studies
using this combination to successfully reverse humoral
rejection was from Montgomery et al. [46]. The same
group subsequently used this combination therapy success-
fully to reduce pretransplant DSA titers in sensitized patients
to allow successful transplantation [46].
A retrospective study analyzed one-year graft outcomes
of 16 patients with AMR treated with PP and IVIG and 43
ACR patients and found similar overall graft survival of 81%
and 84%, respectively, indicating the eﬀectiveness of these
therapies in improving outcomes of acute AMR [47].
Plasmapheresis is generally well tolerated. Side eﬀects are
relatively uncommon and are related to the use of vascular
access (infections, bleeding), volume removal, type of re-
placement ﬂuid used (coagulopathy, hypovolemia, allergic
reactions and a small risk of blood borne infection transmis-
sion), hypocalcemia, and side eﬀects related to use of antico-
agulants [48].
8.3. Immunoadsorption with Protein A (IA). IA is currently
not used in the United States.Journal of Transplantation 5
IAwasstudiedinarandomizedcontrolledtrialinEurope
where it proved very successful in reversing severe AMR
[49]. Both arms underwent a switch to tacrolimus from
cyclosporine, along with treatment for ACR (steroids/ATG)
as needed. The study was initiated at a time when PP and
IVIG were still not universally used for AMR treatment.
Thestudywasstoppedearlybecauseofsigniﬁcantsuccess
rate in the IA group (80% versus 20%). It was, however,
a small study (5 patients in each group), with a higher
prevalence of diﬀuse C4d in the control group. Considering
the widespread acceptance of IVIG and PP for treatment of
AMR and unavailability of IA in the USA, a head-to-head
study of IA with PP and IVIG will be necessary to prove its
superiority, prior to its acceptance as an alternative to IVIG
and PP.
8.4. Rituximab. Rituximab is an anti-CD20 monoclonal
antibody that induces profound depletion of B-cells and was
initially approved for the treatment of B-cell lymphoma.
It has since been tested in multiple immune-mediated
disorders with varying degrees of success. Rituximab has
been used to treat AMR in a number of uncontrolled studies.
Most of the studies reported so far with the use of
Rituximab have reported favorable outcomes. Becker et
al. treated 27 patients with AMR with a single dose of
rituximab. Twenty-two of these patients also received ATG
and plasmapheresis [50]. At a mean of 605 days of followup,
only 3 grafts were lost to rejection. Faguer et al. also reported
81% graft survival at 20 months in 8 patients with the
use of 4 doses of Rituximab along with PP, mycophenolate,
tacrolimus and steroids [51]. Kaposztas et al. reported their
experience with use of Rituximab in combination with PP.
Twenty-six patients were treated with Rituximab along with
PP and IVIG [52]. The graft outcomes were compared to
historical controls who had been treated with PP ± IVIG
alone. The two-year graft survival for patients treated with
rituximab plus PP was signiﬁcantly better at 90% when
compared to the 60% survival in the PP cohort. However,
the doses of IVIG were higher in the Rituximab group, and
the use of IVIG was also statistically associated with a better
graftoutcomeonKaplan-Meieranalysis,raisingconcernsfor
a confounding eﬀect. Lefaucheur et al. also compared the use
of2-weekdosesofRituximabalongwithhigh-doseIVIGand
PP with historical controls who had received high-dose IVIG
alone and reported a 91.7% graft survival, compared to 50%
with high-dose IVIG alone [53]. The mechanism of action
of Rituximab in AMR is not clear, given that the plasma
cells do not express CD20 on their surface. However, the
depletion of CD20-positive subset of B-cells may attenuate
the antibody generation process. The standard dosing of
Rituximab is 375mg/m2/wk for 2–4 weeks. Rituximab
results in prolonged and profound B-cell depletion which
may cause reactivation of latent viruses such as hepatitis
B, C, cytomegalovirus (CMV), and also mycobacterium
tuberculosis. It also carries a boxed warning for progressive
multifocal leukoencephalopathy (PML) caused by JC virus.
Patientscanalsomanifestacuteinfusionreactions,which
usually occur within 30–120 minutes and may be mild or
severe, such as bronchospasm, angioedema, acute respira-
tory distress syndrome, cardiogenic shock, and anaphylaxis.
These have often been reported in leukemic patients with
high pretherapy leukocyte counts [54].
8.5. Change of Maintenance Immunosuppression (IS). Initi-
ation or augmentation of anti B-cell maintenance therapy is
routinelydonewhenAMRisidentiﬁed.Themostcommonly
used agent for this purpose is mycophenolate mofetil. It is
also common practice to change to a calcineurin-based im-
munosuppression, speciﬁcally to tacrolimus, if patients are
not on a calcineurin inhibitor (CNI).
8.6. Bortezomib. Bortezomib is a novel proteosome inhibitor
that is approved for the treatment of multiple myeloma.
Proteasomes are involved in breakdown of ubiquitinated
proteins and are present both in the nucleus and cytoplasm.
Inhibition of proteasomes can lead to decreased nuclear
factor-Kappa B activation, cell cycle arrest, endoplasmic
reticulum stress, and increased cell apoptosis [55]. This
action is pronounced in plasma cells likely because of the
high antibody turnover and high endoplasmic reticulum
activity. A number of groups have investigated the use of
bortezomib in solid organ AMR and have generally reported
favorable results. There is, however, no randomized trial thus
far and in most cases, bortezomib was used after standard
therapies for AMR failed, that are, IVIG and PP [56–63].
Many similar case series and case reports continue to be
reported with good outcomes in AMR with bortezomib.
However, one study reported patients with subclinical AMR
and positive DSAs in whom bortezomib monotherapy did
not result in any signiﬁcant reduction of DSA levels [64].
The authors and the editorial caution against the use of
bortezomib as primary therapy for AMR without strong
evidence from randomized studies. However, this agent
appears to be a promising strategy and its role in AMR is
still evolving. Gastrointestinal side eﬀects, neuropathy, and
hematologicaltoxicityarethemainsideeﬀectsofbortezomib
and need to be carefully monitored. Dosing in most of
these reports has been the standard myeloma dosing of
1.3mg/m2/ w e e k ,w i t h4d o s e sg i v e no v e r2w e e k s .
8.7. Eculizumab. Eculizumab is a humanized monoclonal
antibody directed against complement protein C5. It binds
to the C5 protein with high aﬃnity, thereby inhibiting
conversion of C5 to C5b and preventing formation of the
membrane attack complex (C5–9). Initially approved for
use in paroxysmal nocturnal hemoglobinuria (PMH), it
was also recently approved for use in atypical hemolytic-
uremic syndrome. Prior vaccination against meningococcus
andpneumococcusisnecessary.OnedoseofEculizumabwas
used with IVIG and rituximab in a patient with severe AMR,
who recovered from the AMR but died of a fatal pulmonary
hemorrhage a few months later [65]. A prospective study
compared the outcomes of using eculizumab to prevent
acute AMR and TG after transplantation in a series of
HLA-sensitized pretransplant positive-FXM patients (n =
26). The incidence of AMR at 3 months was signiﬁcantly6 Journal of Transplantation
less compared to an historical control group (7.7% versus
41.2%), although the presence of C4d in patients with DSA
did not diﬀer between the study and controlgroup, thus pro-
viding evidence for the downstream activity of eculizumab
in blocking the complement pathway. The use of eculizumab
also resulted in a reduced need for PP. The one-year TG
prevalence was also low with only one (6.7%) of the 15
patients in the eculizumab group developing TG compared
to 15 (35.7%) of the 42 controls. Most patients in the treat-
ment group received weekly eculizumab for 4–8 weeks while
onepatientneededayearofeculizumabbecauseofpersistent
FXM positivity [66]. No signiﬁcant complications were re-
ported during the study period. Although not a randomized
study, this series serves as a proof of concept for the use of
terminal complement pathway inhibitors in treating AMR. A
majorlimitationforitsuseatthepresenttimeisitsextremely
high cost. However, a multicenter prospective randomized
trial is being planned to study its eﬃcacy and should help
answer some of the questions regarding its role in AMR.
Splenectomy It has also been used in resistant AMR
patients with good success rate [67, 68]. However, because of
the long term risk of infections in immunosuppressed indi-
viduals and the surgical risks involved, this is not a common-
ly used therapy for AMR.
Acute cellular rejection frequently coexists with AMR
and needs to be treated aggressively with either steroids or
T-cell depleting therapies such as Antithymocyte globulin
(ATG). The role of these T-cell depleting therapies in AMR
has not been clearly studied in patients with pure AMR or
AMR with low grades of ACR. The use of these agents may
reduce the T-cell stimuli that are driving the B-cell-mediated
antiallograftresponses,therebyhelpingtogainbettercontrol
oftheAMRprocess.Indirectproofcanbeobtainedfromone
study that reported no signiﬁcant change in graft outcomes
between C4d-positive and negative cases. However, there
was aggressive use of antilymphocyte therapy to treat C4d-
positive cases which might have improved outcomes in this
group of patients [69].
9.CourseandPrognosis
It has been shown in multiple studies that AMR portends
worseoutcomeintermsofgraftsurvivalatoneandﬁveyears.
Some of these studies were reported prior to the utilization
of aggressive therapies that are currently in use for AMR and
often serve as historical controls for trials of newer therapies
for AMR. Lederer et al. reported a 4year 50% graft survival
for C4d+ patients compared to a 8year 50% graft survival
forC4d-patients [70].Poduvaletal.reporteda oneyeargraft
loss of 65% for grafts with diﬀuse C4d+ diagnosis compared
to 33% for focal and negative C4d grafts [71]. One study,
however,notednodiﬀerencebetweenC4d+andC4d−grafts
with up to 3 years followup. However, patients with C4d+
were treated more aggressively with antilymphocytic therapy
(ATG and OKT3) [69].
The signiﬁcance of C4d+ allograft biopsies appears to
diﬀer based on whether the transplantation was ABO or
HLA incompatible [72]. Multiple studies have documented
presence of diﬀuse C4d with no allograft dysfunction and
with no histologic evidence of AMR in protocol biopsies of
ABO incompatible transplants [73, 74] .T h ep r e s e n c eo fC 4 d
in these patients was also shown to have no adverse outcome
and in fact was associated with a trend toward better scores
of chronicity and less TG at subsequent followup [73]. In
contrast, the presence of diﬀuse C4d+ in ABO compatible
HLA-mismatched kidney transplantation appears to be very
commonly associated with neutrophil margination suggest-
ing ongoing antibody-mediated rejection [72].
The signiﬁcance of focal C4d on biopsies is currently still
being evaluated and is not entirely clear. A signiﬁcant num-
berofthesebiopsiesmaynotbeassociatedwithhistologicev-
idence of AMR, but its presence has still been associated with
inferior graft outcomes [75, 76]. Graft outcomes with a diag-
nosis of TG are poor, with graft survival of 60% at 5 years
compared to >90% without TG [8].
10. Management of Patients with
PretransplantationHLASensitization
Improvements in HLA typing and DSA identiﬁcation have
increased our ability to identify high-risk recipients who
may be at risk for antibody-mediated rejection posttrans-
plantation. For patients who are highly sensitized or those
with ABO or HLA incompatible living donors, there are
at present four options available for successful transplanta-
tion. Patients can undergo desensitization protocol followed
by a kidney transplant provided they can achieve suﬃcient
reductions in DSA titers and become crossmatch negative.
Even with successful transplantation after desensitization,
these patients remain at increased risk for AMR. They
also have reduced graft survival compared to nonsensitized
patients. However, their outcomes are still superior when
compared to remaining on dialysis [77]. Patients can also
undergo a paired living kidney donation (PKD) involving
2 or more donor recipient pairs. Another potential option
less commonly used is List paired donation (LPD) which
involves the option of a recipient with an incompatible living
donor getting a deceased donor kidney from a waiting list
in return for the living donor donating it to the intended
recipient on the transplant waiting list [78]. The least favor-
able option would be to remain on the deceased donor list
waiting for a compatible donor. However, for some highly
sensitized patients with living donors, transplantation by
paired exchange or list-paired donation may not be possible
[78]. These patients should preferably undergo desensitiza-
tion to improve the likelihood of transplantation which, as
mentioned earlier, has been shown to oﬀer improved patient
survival compared to waiting on the transplant list [77].
11. Summary
Antibody-mediated rejection is an important cause of acute
and chronic graft failure. Improvements in HLA technology
along with the recognition of the role of C4d in AMR have
revolutionized the understanding of this important entity.
New research is attempting to elucidate the mechanismsJournal of Transplantation 7
and epidemiology of C4d-negative antibody-mediated rejec-
tion processes. Further research should help clarify the iden-
tiﬁcation, prognosis, and treatment of these C4d-negative
AMRs. Therapies for AMR are still not optimal with high
rates of graft loss leading to poor patient outcomes. Newer
therapies, such as bortezomib and eculizumab that target
novel pathways in the AMR process are promising but will
need further randomized studies before becoming widely
used.Studieswillneedtobeperformedtodeterminethebest
use, either alone or in combination, of the myriad number
of therapies currently available. Transplantation of sensitized
patients remains a diﬃcult problem. However, developments
suchaspairedkidney donation anddesensitizationprotocols
are continuously improving the rates of transplantation in
this diﬃcult to transplant population.
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